Nitya G. Ray
Plus aucun poste en cours
Fortune : 57 302 $ au 31/03/2024
Profil
Nitya G.
Ray worked as a Director of Bioprocess Development at Forticell Bioscience, Inc. from 1997 to 2001.
He then worked at Progenics Pharmaceuticals, Inc. for 17 years, starting as a Senior Vice President of Manufacturing in 2001 and ending as an Executive Vice President in 2018.
In 2017, he briefly worked as an Executive Vice President at Actinium Pharmaceuticals, Inc. before becoming the Chief Technology Officer at CytoDyn, Inc. in 2018.
Dr. Ray received his undergraduate degree from Jadavpur University and his graduate and doctorate degrees from Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CYTODYN INC.
0,04% | 11/09/2023 | 351 545 ( 0,04% ) | 57 302 $ | 31/03/2024 |
Anciens postes connus de Nitya G. Ray
| Sociétés | Poste | Fin |
|---|---|---|
| CYTODYN INC. | Chief Operating Officer | 19/04/2022 |
| ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 21/12/2018 |
| PROGENICS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2018 |
Forticell Bioscience, Inc.
 Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Corporate Officer/Principal | 01/01/2001 |
Formation de Nitya G. Ray
| Rutgers State University of New Jersey | Doctorate Degree |
| Jadavpur University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CYTODYN INC. | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Forticell Bioscience, Inc.
Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
